Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
13.05
+0.55 (+4.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
April 11, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
March 22, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals: Q3 Earnings Insights
March 10, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 03, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
February 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 24, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals: Q2 Earnings Insights
December 09, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the...
Via
Benzinga
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 10, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
November 08, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
September 21, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Why KalVista Pharmaceuticals' Stock Is Trading Higher Today
September 15, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of...
Via
Benzinga
Exposures
Product Safety
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
September 14, 2021
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of...
Via
Benzinga
Exposures
Product Safety
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
September 14, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
August 23, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 13, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.